FDA Issues Emergency Authorization for Use of Zika Test From Roche

ZURICH (Reuters) -
Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann
Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland. (Reuters/Arnd Wiegmann)

The U.S. Food and Drug Administration (FDA) on Monday issued emergency authorization for use of a Zika diagnostics test from Swiss drugmaker Roche, skirting normal approval channels as the regulator moves to fight the disease’s spread.

Zika virus, detected in Brazil and elsewhere last year before spreading to the Americas, is associated with microcephaly, a birth defect characterized by an unusually small head and potential developmental problems.

Through last week, the United States reported 2,517 Zika cases, 29 of which were likely acquired locally in Florida through mosquito bites and the rest brought in by travelers, the U.S. Centers for Disease Control and Prevention (CDC) said.

A worker fogs the corridor of a public housing estate in the vicinity where a locally transmitted Zika virus case was discovered, in Singapore August 29, 2016. REUTERS/Edgar Su
A worker fogs the corridor of a public housing estate in the vicinity where a locally transmitted Zika virus case was discovered, in Singapore, Monday. (Reuters/Edgar Su)

Some 9,000 additional cases have been reported in U.S. territories, including Puerto Rico.

With FDA approval, Roche’s test now can be used to screen patients exhibiting Zika symptoms that meet CDC criteria, including fever, rash, joint pain and red eyes. Samples will be sent for analysis to specially certified U.S. laboratories with the appropriate equipment, a Roche spokesman said.

“The LightMix Zika test is an easy-to-use molecular diagnostic test that enables healthcare professionals to quickly detect the virus,” said Uwe Oberlaender, the head of molecular diagnostics at Basel-based Roche.

The FDA issues such Emergency Use Authorization during public health emergencies, to quickly deploy unapproved medical products for as long as they are needed.

As the number of Zika cases caused by local Aedes aegypti mosquitoes in Florida mounts and travelers from elsewhere continue to arrive with the disease, the FDA last week recommended universal testing of donated blood across the United States.

In March, Roche won separate investigational approval from the FDA for its Cobas 6800/8800 testing system to be used to test blood at U.S. blood centers including in Puerto Rico, where about 1 percent of donated blood has so far tested positive for the virus.

In Brazil, Zika virus has been linked to more than 1,800 cases of microcephaly, and U.S. officials expect as many as 270 cases in Puerto Rico.